Pages that link to "Q36022784"

The following pages link to Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? (Q36022784):

Displaying 45 items.

• Proteomics in Traditional Chinese Medicine with an Emphasis on Alzheimer's Disease (Q26777933) (← links)
• Cellular model of neuronal atrophy induced by DYNC1I1 deficiency reveals protective roles of RAS-RAF-MEK signaling. (Q27339937) (← links)
• Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 (Q34408888) (← links)
• Why so few drugs for Alzheimer's disease? Are methods failing drugs? (Q34440659) (← links)
• Platelets, a reliable source for peripheral Alzheimer's disease biomarkers? (Q34500658) (← links)
• The impact of human and mouse differences in NOS2 gene expression on the brain's redox and immune environment (Q34584761) (← links)
• Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity (Q34630570) (← links)
• Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study (Q35195840) (← links)
• Older patients are still under-represented in clinical trials of Alzheimer's disease (Q36103290) (← links)
• Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire (Q36298580) (← links)
• Sex and gonadal hormones in mouse models of Alzheimer's disease: what is relevant to the human condition? (Q36473640) (← links)
• Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story (Q36475090) (← links)
• Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices? (Q37055784) (← links)
• Patient heal thyself: modeling and treating neurological disorders using patient-derived stem cells (Q37199722) (← links)
• Retinal nerve fiber layer thickness in amnestic mild cognitive impairment: Case-control study and meta-analysis. (Q37303033) (← links)
• Alzheimer's disease drug development: old problems require new priorities (Q37363992) (← links)
• Resurrecting clinical pharmacology as a context for Alzheimer disease drug development (Q37387281) (← links)
• Phenserine Efficacy in Alzheimer's Disease (Q37510264) (← links)
• A new regulatory road-map for Alzheimer's disease drug development (Q37510270) (← links)
• Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances? (Q37524877) (← links)
• Lost in Translation: Neuropsychiatric Drug Development (Q37527193) (← links)
• Was phenserine a failure or were investigators mislead by methods? (Q37530878) (← links)
• Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier (Q37971834) (← links)
• Alzheimer disease therapy--moving from amyloid-β to tau. (Q38161786) (← links)
• Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. (Q38810754) (← links)
• An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). (Q39862371) (← links)
• Looking for a generic inhibitor of amyloid-like fibril formation among flavone derivatives. (Q40484092) (← links)
• A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer's mouse model via an HSF1-mediated mechanism. (Q41822922) (← links)
• Drug discovery and development: Role of basic biological research (Q47108962) (← links)
• Does traumatic brain injury hold the key to the Alzheimer's disease puzzle? (Q47677964) (← links)
• Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease (Q47724056) (← links)
• Non-Clinical Contribution to Clinical Trials during Lead Optimization Phase (Q49407465) (← links)
• Overcoming barriers in cognitive assessment of Alzheimer's disease (Q50043207) (← links)
• Many are called, yet few are chosen. Are neuropsychiatric clinical trials letting us down? (Q51824177) (← links)
• Idalopirdine for Alzheimer's disease: written in the stars. (Q53357863) (← links)
• The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer's disease treatment? (Q54249538) (← links)
• Accurate pain reporting training diminishes the placebo response: Results from a randomised, double-blind, crossover trial. (Q55252484) (← links)
• Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease. (Q55297754) (← links)
• PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment (Q57476483) (← links)
• Re-thinking Alzheimer's disease therapeutic targets using gene-based tests (Q57479938) (← links)
• Neurotheranostics as personalized medicines (Q64819927) (← links)
• Nutrients in Alzheimer's Disease: The Interaction of Diet, Drugs and Disease (Q91246348) (← links)
• The Configuration of the Perivascular System Transporting Macromolecules in the CNS (Q92698789) (← links)
• Perifovea retinal thickness as an ophthalmic biomarker for mild cognitive impairment and early Alzheimer's disease (Q92799333) (← links)
• Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions (Q93055003) (← links)